Researchers at the Icahn School of Medicine at Mount Sinai in New York City found that adding a brief safety reminder to prompts reduced potentially harmful clinical choices in 19 of 20 large language models tested. The study, published Sept.…
The Latest
Tony Swart has been appointed CEO of Aspen Mountain Medical Center in Rock Springs, Wyo. Mr. Swart brings 19 years of healthcare experience, including hospital operations, finance, supply chain and service development, according to an Oct. 7 hospital news release.…
Philadelphia-based Penn Medicine received a $25 million gift from the Smilow Foundation to establish the Smilow Center for Precision Therapeutics, which will focus on developing gene-editing and other precision therapies for cardiovascular disease. Four things to know: 1. The center…
Thirty-one Democratic and independent lawmakers are pressing CDC Director Erica Schwartz, MD, on the Trump administration’s childhood vaccine overhaul and the agency’s measles response. The lawmakers, led by Sen. Michael Bennet, D-Colo., and Rep. Kim Schrier, MD, D-Wash., sent Dr.…
Ninety days reaches well beyond the operating room, rewarding hospitals that plan for recovery before the first incision.
Birmingham, Ala.-based UAB Medicine is hiring an associate vice president of patient experience to lead its Office of Patient Experience and Engagement, according to a job posting on the health system’s careers site. The executive will build and advance a…
Deal complexity is increasing, driven in part by who is coming to market.
Make pediatric language access a strength of your health system. This whitepaper shows health system leaders how a child-centered approach puts children at ease and strengthens family trust, supporting your quality and equity goals. The focus is the child’s experience…
Presented by:
Nearly one-third of newly licensed nurse practitioners in four states were educated at for-profit programs in 2024, up from 2.4% in 2010, a recent study found. The study, published Oct. 6 in Annals of Internal Medicine, analyzed 117,156 nurse practitioners…
The FDA has approved Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms are inadequately controlled with H1 antihistamines. Rhapsido is the first treatment approved for symptomatic dermographism, according to an Oct. 7 news release. The oral selective BTK…